Skip to content

Long-term Outcomes of Endoscopic Resection (ER) of Lesions of the Duodenum and Ampulla

Outcomes of Endoscopic Resection of Mucosal and Submucosal Lesions in the Duodenum and Ampulla

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02306603
Acronym
OERDA
Enrollment
200
Registered
2014-12-03
Start date
2014-10-31
Completion date
2027-04-30
Last updated
2025-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoma, Villous

Brief summary

This research project, 'Outcomes of endoscopic resection of mucosal and submucosal lesions in the duodenum and ampulla'. The research project is aiming to determine the most effective and safe way to remove such lesions.

Detailed description

Endoscopic resection (ER) of superficial lesions of the duodenum and ampulla is a safe and effective surgery sparing modality in experienced hands. It is often curative of dysplastic lesions and is associated with minimal complications and high patient acceptance (1-5). Westmead Hospital has accumulated a significant amount of experience in the removal of such lesions; however, there is limited research to document the long term outcomes of patients undergoing endoscopic resection.The purpose of this study is to evaluate the long-term outcomes of ER of superficial lesions of the duodenum and ampulla.

Interventions

PROCEDUREEndoscopic Mucosal Resection

Sponsors

Professor Michael Bourke
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

\* Duodenal and ampullary lesion \> 10mm * Lesion limited to the mucosal and/or submucosal layer (T1 lesion) * Aged 18 years or older

Exclusion criteria

* Lesion less than 10mm * Duodenal or ampullary lesion involves the muscularis propria (T2 lesion) on other staging modalities such as endoscopic ultrasonography (EUS) * Aged younger than 18 years

Design outcomes

Primary

MeasureTime frame
Observed procedural data: Number of Participants with Adverse Events as a Measure of Safety and Tolerability Outcomes14 days

Secondary

MeasureTime frameDescription
Analysis of the costs of this procedure compared to previous treatments14 daysPerform cost-utility analyses comparing different treatment approaches for duodenal and ampullary lesions

Countries

Australia

Contacts

Primary ContactMichael Bourke, MBBS
michael@citywestgastro.com.au88905555

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026